Classys steps up European market push with QUADESSY and VICLARA

[Financial News] Classys is stepping up its push into the European medical aesthetics market with new products. The company is diversifying its portfolio by adding radiofrequency (RF) microneedling and skincare devices to its existing business, which has centered on lifting equipment, as it pursues a transition into a comprehensive medical aesthetics company.
On the 13th, Classys said it held a European user meeting on the 10th at Park Plaza London Riverbank in London, UK, where it announced the official European launch of its RF microneedling device QUADESSY and plans to launch its skincare device VICLARA in December. About 100 people, including representatives of major European distributors and medical professionals, attended the event.
QUADESSY combines invasive and non-invasive RF technologies. At the event, U.S. plastic surgeon Jeffrey Antimarino shared six months of clinical experience and treatment cases. Classys plans to develop QUADESSY into a key product for expanding its presence in the European RF microneedling market.
VICLARA, slated for a European launch in December, was also unveiled for the first time at the event. The platform integrates multiple skincare functions into a single device, with a focus on expanding the treatment options available at clinics and improving operational efficiency. Three dedicated ampoule solutions reflecting K-beauty characteristics were also introduced.
Classys is also continuing to grow its existing lifting-device business. Cumulative European sales of its focused ultrasound (HIFU) device Ultraformer MPT and monopolar RF device Volnewmer have exceeded 3,500 units. The company aims to sell at least 350 more units in the fourth quarter of this year.
The company is also expanding combination treatments using the two devices. Volformer, a global treatment program using Ultraformer MPT and Volnewmer, is building its presence in Europe as a premium combination lifting treatment. The event also featured treatment protocols for different facial and body areas, as well as full-face treatment cases using 800–1,000 shots depending on the condition of the skin and tissue.
Classys plans to diversify the growth drivers of its European business by adding QUADESSY and VICLARA to its existing lifting devices. It plans to expand new product launches, collaboration with medical professionals, clinical training and local marketing, focusing on key countries.
Classys CEO Yoon Jun-oh said, "QUADESSY and VICLARA are strategic products that will play a key role as Classys moves beyond its position as a leader in lifting in Europe to become a comprehensive medical aesthetics company. We will rapidly expand the rollout of these new products and continue to grow in the European market."

[email protected] Jung Sang-hee Reporter